CA9 and breast cancer: As a direct transcriptional target of hypoxia-inducible factor 1α, CAIX is overexpressed in several hard-to-treat tumors, including ccRCC, CRC, breast cancer, and PDAC (2,9–11), making it a promising therapeutic target.